Current perspectives of mitochondria-targeted antioxidants in cancer prevention and treatment
Oxidative stress nearly always accompanies all stages of cancer development. At the early stages, antioxidants may help to reduce reactive oxygen species (ROS) production and exhibit anticarcinogenic effects. In the later stages, ROS involvement becomes more complex. On the one hand, ROS are necessa...
Saved in:
Published in | Frontiers in cell and developmental biology Vol. 11; p. 1048177 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
16.03.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Oxidative stress nearly always accompanies all stages of cancer development. At the early stages, antioxidants may help to reduce reactive oxygen species (ROS) production and exhibit anticarcinogenic effects. In the later stages, ROS involvement becomes more complex. On the one hand, ROS are necessary for cancer progression and epithelial-mesenchymal transition. On the other hand, antioxidants may promote cancer cell survival and may increase metastatic frequency. The role of mitochondrial ROS in cancer development remains largely unknown. This paper reviews experimental data on the effects of both endogenous and exogenous antioxidants on cancerogenesis focusing on the development and application of mitochondria-targeted antioxidants. We also discuss the prospects for antioxidant cancer therapy, focusing on the use of mitochondria-targeted antioxidants. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Edited by: Saverio Marchi, Marche Polytechnic University, Italy Alessandro Rimessi, University of Ferrara, Italy Reviewed by: Daniela Valenti, National Research Council (CNR), Italy This article was submitted to Signaling, a section of the journal Frontiers in Cell and Developmental Biology |
ISSN: | 2296-634X 2296-634X |
DOI: | 10.3389/fcell.2023.1048177 |